GORE MEDICAL RECEIVES BREAKTHROUGH DEVICE DESIGNATION FOR THE GORE® EXCLUDER® THORACOABDOMINAL BRANCH ENDOPROSTHESIS

CAUTION: Investigational device. Limited by United States law to investigational use.

Apr 12, 2022

Nominees Announced for 2016 Pioneers in Performance Awards for North America; Online Voting Opens at www.PioneersInPerformance.com

Awards program honors medical specialists advancing therapy and improving patient and clinical performance through active collaboration

FDA Approves GORE® VIABAHN® Endoprosthesis for Revision of the Arteriovenous Access

Flexibility and Durability to Aid Hemodialysis Patients

Gore and AAAneurysm Outreach Partner to Increase Early Detection of Abdominal Aortic Aneurysm (AAA)

New Campaign Will Employ Awareness, Community Outreach, and Patient Screening to Fight AAA

Final Subject Enrolled in Early Feasibility Study of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis

Antegrade iteration accepted into study – advancing this branched, all-in-one system

GORE® TIGRIS® Vascular Stent Gains FDA Approval for Treatment of Peripheral Artery Disease

Novel device combines proven technology with modern adaptations to provide support in even the most challenging anatomies

GORE® EXCLUDER® AAA Endoprosthesis Gore Completes Primary Enrollment for the Gore EXCLUDER® Iliac Branch Clinical Study

62 patients enrolled in US investigational device exemption clinical study to assess first complete, low-profile system for managing common iliac artery aneurysms or aorto-iliac aneurysms

Gore Receives FDA Approval for 25 cm GORE® VIABAHN® Endoprosthesis

Longest stent-graft introduced in the United States

Market-leading TEVAR Device is First to Surpass 100,000 Devices Distributed Worldwide

Proven, durable device leads the market, continues to impact lives

Celebrating the 20th Anniversary of the GORE® EXCLUDER® Device

With two decades of evolution and more than 300,000 patients treated* worldwide, this trusted, market-leading EVAR device continues to advance patient care